ACC is committed to compliance with all applicable equal employment laws. ACC In-house Jobline listings may not explicitly or implicitly discriminate on the basis of any prohibited factor.
Listings on the ACC In-house Jobline are for in-house attorney positions only. While we do not accept non-attorney corporate job listings, if you are hiring a corporate legal operations professional, contact LawDepartmentOps@ACC.com. By posting a job on the ACC In-house Jobline or using the service as a job seeker, you are agreeing to comply with our Terms and Conditions, including those relating to discrimination. The system administrator may delete postings, which do not comply. Employer postings removed by ACC are not subject to refund.
We are very interested in your thoughts as we continue to develop the ACC In-House Jobline to better serve your needs. If you have questions about ACC In-house Jobline, please call our helpdesk at: 1-888-491-8833 Ext. 1125 (Extension Required).
The Associate Director - Legal Affairs will provide general legal support for Clovis Oncology's R&D and Commercial operations, primarily by handling a wide range of complex agreements for our growing biotechnology company.
Provide legal support and substantive advice primarily to Clovis Oncology's R&D functions, including Clinical Development, Clinical Operations, Translational Medicine, and Medical Affairs, and secondarily to the Commercial functions of the company, including Marketing, Project Management, IT, and Finance.
Draft, review, negotiate, and manage a high volume of R&D-related agreements, including confidentiality, material transfer, services, consulting, sponsored research, clinical trial and investigator-initiated trial agreements.
Draft, review, negotiate, and manage a variety of commercial agreements, including confidentiality, consulting, and services agreements.
Support project management activities and governance of programs.
Maintain frequent contact with all client functions within the company, managing requests and prioritization of projects.
Significant experience drafting, reviewing, and negotiating a wide variety of complex pharma-related R&D agreements.
Excellent skills in verbal and written communication, with ability to distill complex legal issues to essential elements for clients throughout the organization with different abilities and responsibilities.
Strong organizational skills in order to prioritize and manage multiple time-sensitive projects simultaneously; willingness to assume heavy workload to meet timing and project needs.
A demonstrated ability to grasp scientific and technical concepts quickly.
Ability to collaborate, as well as work independently, balancing competing priorities.
Strong client-support skills.
Attention to detail.
High business acumen with the ability to appropriately balance legal and business risks in an ethical and compliant manner.
Education and Experience
JD degree from an accredited law school.
Excellent academic and law firm credentials.
Must have 3 - 6 years of relevant prior experience handling complex commercial contracts at a law firm with a nationally recognized Life Sciences/Pharma/Biotech practice or in-house at a pharma/biotech organization.
Science background a plus.
Must be licensed to practice law in at least one (1) state and in good standing.
We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is ...most likely to benefit from its use.Our first commercial product and lead product candidate, rucaparib, is an oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3. We hold global development and commercialization rights for rucaparib. RubracaTM (rucaparib) is the first and only oral, small molecule PARP inhibitor approved in the United States by the FDA as monotherapy treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Rucaparib is being explored in a variety of solid tumor types with significant BRCA and BRCA-like populations, including ovarian, prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers. In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). Clinical development for each of these candidates has ceased and we continue to provide drug to patients whose clinicians recommend continuing therapy. We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.